My Semi-annual review of GERN
GERN (market cap is $0.855B was $0.870B)
?
Geron (GERN) is a biotech that recently received FDA approval for their blood disorder treatment. Their product works on blood-related cancers, and may extend to other cancers.
?
Geron is a biotech, but seems a bit withered. I've held the stock since circa 1999. Then, they were leading edge, a major innovator, had grand plans for dramatically expanding human lifespans; and had a management team and philosophy that impressed me with their wisdom and insights into public reactions.
?
Delays inspired and required the sale of much of their intellectual property and divisions, which leaves them with the telomerase-related treatments. They may be more than good enough for the company to become impressively useful and profitable. Sadly, subsequent management teams seem to have lost the startup vigor, and the long term grand plan for revolutionizing medical care. Now, management seems like, well, managers, managers who are executing a plan but not a vision.
?
As I understand it, managing cell telomeres can manage to treat cell death by encouraging some cells to die (cancer) and discouraging others from dying prematurely (auto-immune diseases). Those two general applications cover a broad swath of medical issues, some of which have few or poor treatment options. Whether management recognizes the potential is highly uncertain.
?
DISCLOSURE LTBH since 1999 and continuing to hold, but do not plan on buying more unless I see significant positive changes at the company.
I continue to hold because selling so low has little benefit and I am an optimist.
(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net
|
